|
0
|
|
Evaluation of targeted and immune combination therapies in a rat model of hormone receptor-positive breast cancer.
(pnas.org)
|
Rojas-Jimenez E
…
Polyak K
PNAS
2026-02-10
|
#modeling
#immunity
#cancer
#immunotherapy
|
|
0
|
|
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.
(bmj.com)
|
You R
…
Chen MY
BMJ
2026-02-10
|
#cancer
#clinical trial
#immunotherapy
#chemoradiotherapy
#pd-1
|
|
0
|
|
Mitochondrial transfer in the HSC-HCC-macrophage network shapes hepatocellular carcinoma progression.
(pnas.org)
|
Zhang L
…
Jiang N
PNAS
2026-02-10
|
#nanoparticles
#cancer
#immunotherapy
#microenvironment
#mitochondria
|
|
0
|
|
KRAS-driven protein disulfide isomerase family A member 6 expression suppresses PRKR-like endoplasmic reticulum kinase-mediated immunogenic cell death to desensitise pancreatic ductal adenocarcinoma to immune checkpoint blockers.
(gut.bmj.com)
|
Wang R
…
Su H
Gut
2026-02-10
|
#amr
#cancer
#immunotherapy
#immunogenicity
#tumor microenvironment
|
|
0
|
|
Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers.
(pnas.org)
|
Tendler S
…
Lewis JS
PNAS
2026-02-10
|
#antibody
#cancer
#immunotherapy
#neuroendocrine
#radiopharmaceuticals
|
|
0
|
|
Trogocytosis-orchestrated CLDN18.2-"dressed" CD8(+) T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade.
(gut.bmj.com)
|
Zhou T
…
Hao J
Gut
2026-02-10
|
#metabolism
#cancer
#immunotherapy
#cytotoxicity
#pancreatic
|